Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model  OAK RIDGE, TN, July  29, 2026  (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Daxor Expands Outpatient BVA Program in Midwest, Aiming to Cut Readmissions

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model  OAK RIDGE, TN, July  29, 2026  (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Daxor announced a new outpatient Blood Volume Analysis program via its ezBVA Lab send-out model at a Kansas facility, expanding Midwest access to precise volume metrics with 98% accuracy in 24 hours and no capital equipment. The initiative could accelerate BVA adoption, improve decongestion decisions, and reduce readmissions, strengthening revenue opportunities through services and lab testing.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Daxor launches outpatient BVA program in eastern Kansas using ezBVA Lab.</li><li>Program provides 98% accurate blood-volume measurements within 24 hours with no capex.</li><li>Expansion aims to reduce readmissions and optimize decongestion with objective data.</li><li>CEO and CMO emphasize improved patient outcomes and system-wide cost reductions.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Daxor Corporation (DXR)</strong>: Announces new outpatient BVA program; potential revenue growth from expanded services and Midwest deployment.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This is a corporate development announcing strategic expansion of Daxor&#039;s diagnostic services, highlighting growth potential in outpatient BVA adoption.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Midwest outpatient BVA deployment could boost DXR service revenue.</li><li>98% accuracy and 24-hour turnaround support payer reimbursement potential.</li><li>Expansion to Midwest may unlock new hospital contracts.</li><li>No capital equipment lowers customer acquisition barriers.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: July 29, 2026.</li><li>Outpatient BVA program in eastern Kansas.</li><li>ezBVA Lab turn-key, with 98% accuracy in 24 hours.</li><li>DXR ticker: NASDAQ: DXR; FDA-cleared Blood Volume Analysis.</li><li>ISO-certified operations; 20,000 sq ft U.S. facility.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>DXR could see near-term revenue and utilization upside as Midwest BVA deployments scale over the next 3–6 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify"><i>Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model</i></p>  <p align="justify"><strong>OAK RIDGE, TN, July  29, 2026  (GLOBE NEWSWIRE) -- </strong>Daxor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DXR">DXR</a>), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA<sup>&#x2122;</sup>) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor’s presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics.</p>  <p align="justify">The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood volume measurements within 24 hours—with zero capital equipment or dedicated lab infrastructure required. By directly measuring total blood, plasma, and red cell volume, clinicians can replace subjective fluid estimation with precise, data-backed decongestion strategies that optimize patient outcomes and prevent readmissions through existing reimbursement structures.</p>  <p align="justify"><b>Executive Commentary</b></p>  <p align="justify">"Expanding access to outpatient precision diagnostics is critical to breaking the costly cycle of readmissions. Our turnkey ezBVA Lab service eliminates capital and logistical hurdles, allowing high-volume cardiology centers to seamlessly integrate individualized decongestion care that improves outcomes while lowering overall system costs." <br></br>— Michael Feldschuh, <i>President and CEO of Daxor Corporation</i></p>  <p align="justify">"Relying on clinical estimates for fluid management routinely leaves subclinical hypervolemia unaddressed or leads to over-diuresis. BVA delivers diagnostic accuracy, giving physicians the objective clarity needed to fine-tune therapies, safeguard renal function, and improve opportunities to keep patients safely out of the hospital."<br></br>— John L. Jefferies, MD, MPH, MBA, <i>Chief Medical Officer of Daxor Corporation</i></p>  <p align="justify"><b>About Daxor Corporation</b></p>  <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=S_Ysi1Fs8mvK-GvnPtcpg3nVUoGuPRqycql2AI8jjC5bKB0rL63U-tgK-UCyGAbX7AXXQIxdApGGSFKdcFtAslX0-YKOsXh6q7iC_XnalCM9MgmxBTfdjref7VPBr2Z87dLbm5z2OZF_Mf0uxXDEXguQEy9K0u8s5mQhM9wZ7_wzCwqtQtMyWBoh-n9o2Tj6PB2uxmS79PRODlbSm73jHi9D5ZiFO45qd8GmuYUgQsSOG2KaYJ02OKn1-u_BNO4xwTAYG-y97x0OGiAVno-k4l64hupFS5wAwv9TcW0SMm2Gupuli08anGIMjttuc9sR5DrNSJsbzLNfaoHdvEZBstaKMaQLpFITqBvqUVz9jrc=" rel="nofollow" target="_blank">Daxor Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/DXR">DXR</a>) is tackling healthcare&#39;s &#34;multi-billion-dollar silent crisis&#34;, the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.</p>  <p align="justify">For more information, please visit our website at <a href="https://www.globenewswire.com/Tracker?data=S_Ysi1Fs8mvK-GvnPtcpg-Il7CQnGgmQS9yhVYlGGeORGIRoYupF1N2egia3icPfX_EOOJ3rE2_oUJME_apGTFJLWSyWJYZqfTz3bWhY9EkWSqsDd5rpGSCPtGHZfkBFsUjZXtzakTXOhCu5yal2XIu4SkGrFQwumysHpm8T1G1GbIuP78cl3XyHoaOgL8th2nDx3Pmbt-EkOi4E_lheyc_7rfgZvKl7PqLQn-S04VOIxsqP-BoPGsGpkn1PY0vLl_-uGqcirYQvDDY7iP4OedyiV0qzsJvf_yYeDJIrDpXupfU31u-nBiDp4e6Lv4Flh-mtmZG7vVaHEbHITHM1nL-jprDhMT9YsOeMN1GzYzV_Kanj-Jow0yNJn1GA7Ulsfs7z74JbN8VWHZu953h8cMvyjUJeBbe3PknWG0KyV5GwFDUz2GweX-bDJ3uf0HquAfi9Tmkg2Nu13CpNo2EV_Ga1LcNRB9z7AFKG3BXHfQ9sfmRVoVgPdn62KXcDck_n" rel="nofollow" target="_blank">Daxor.com</a>.</p>  <p align="justify">Sign up to receive news on Daxor’s innovative technology<a href="https://www.globenewswire.com/Tracker?data=S3jwy5GpizYH7zePZNgasYczV7QvciEgENEg8f-1sHq5JPKxyOZU9bK8wRrfZRhb7oSGZ97E9VQtdSN2IeOn_fleOLvbsh7pQzeEztoEV3wyDmBhtzeGxsAWhocxGHQf05z928rjf_6aoL6UW-ShSantTDtXAtMkwL8ekhCmk3MvotUgJ_Hmkq7g_nA1ZBoG27S3Wu1KF7WJiT9n_TTMnWIBjg3Ao_vhynlvzyFYLLoTxn_Fymv7_wmWzIwhe55LcncOKMz348c_rHoZqEGrFGkFOLdUbOxHRCIqL_Kx64zFBWZXKeFWJz1SiR4GT2CirLNhIj6hTcZ0kZkbiWtfWdKyRQI-_5AC4k4jS3mQnRA=" rel="nofollow" target="_blank"> </a><a href="https://www.globenewswire.com/Tracker?data=XBqJaoTZ_tAhgvbCvrRpu1Qy03KmPjShBBzk6Ejw9-gFBvhXg0bim1jLjZWMsDX12GTy8KCSAYz6OeVc_9MS0JwZPwXJXtVo6m-qWYzyVuyohyGYZ8ttyUxLXvoh5LczBR0tfpWKK4FJ1VMahBTlBKOTsJNxzs_J-K4bDI_dCcYYg1VFqS1--8zfNNiN28xr4LSq-19QZ4KFZxgBIdoWCn4JFk8y0LqZaM-wvfuJZ3B2U_xzSdM2gL6onx-1KNZfh0RxnUJtK78bI0rQe4rBfFooItfZw4TXQAKU8a2tFCfjmNPP4PCkxa3LstKR27uG1o5ad2IVF-J6iMzuq4Gn3wtHhlfe3dTjME6julOfwLOSgwx1Eh5xyh7ualrdQ8OZ" rel="nofollow" target="_blank">HERE</a>.</p>  <p align="justify"><b>Forward-Looking Statements</b></p>  <p align="justify">Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</p>  <p align="justify"><b>Investor Relations Contact</b><br></br>Bret Shapiro<br></br>COO – Head of Capital Markets<br></br>COREIR<br></br>516-222-2560 <br></br><a href="https://www.globenewswire.com/Tracker?data=iM-LmUvxIAVSzjupuCWboOpwEf9wb62H4sWTButqeWcxpRicEEvQypsO73XfNorMEvrJ9nOLD-91gW58OWXOkICyyvNQRzGbJB_t00DYz34=" rel="nofollow" target="_blank">brets@coreir.com</a>&#x7C;<a href="https://www.globenewswire.com/Tracker?data=aBl7yNebbCc-fuecV-p6nOA-EjyhjxjxmVYGfJkrpBmQe-ROOAz5czzt79vslrykQUhOrwSDZngCnvsklE2uwymQfGNLtIPrR-jaDRWeB_ue6ur5EmjCJd_laJE4B8D8P-m_I97TT6vbriLjcTalptqqV6zr9Br68Om7u0BMmHs_nEa-7wecWADAR6BchrpW-EXWBcNstkMtRlRRYFmlnQl3pv8fBiYw0J78niXDVmGckiJdNVCSuvQFwVQe6JclT72196ecJFI0VfopPEwcNLzk4LLaZedNE1EpHkk4D1x8VZ-OtgY0_eArOqEtA-0gWfeGdxRkY7-FLaGmarc1FRic8mqzRl_sjTOoMr5V9uA=" rel="nofollow" target="_blank">www.coreir.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwMDc0NiM3NzUwODA2IzIwODQzNDY="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MWVmNjYwOGUtYzYyZi00OTM0LWFjZjQtMWQ0MGFkMzU3NGYxLTEwOTU5MTctMjAyNi0wNy0zMC1lbg==/tiny/Daxor-Corporation.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/24a98cc3-3860-436b-901b-dadb081c5f68"><img src="https://ml.globenewswire.com/media/24a98cc3-3860-436b-901b-dadb081c5f68/small/daxor-logo-thumbnail-png.png" border="0" width="150" height="85" alt="Primary Logo"></img></a></p>

Daxor announced a new outpatient Blood Volume Analysis program via its ezBVA Lab send-out model at a Kansas facility, expanding Midwest access to precise volume metrics with 98% accuracy in 24 hours and no capital equipment. The initiative could accelerate BVA adoption, improve decongestion decisions, and reduce readmissions, strengthening revenue opportunities through services and lab testing.

News insight

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

AI summary

Sentiment rationale

Key facts

Corporate Developments